Amneal Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amneal Pharmaceuticals, Inc.
Amneal Completes Hat Trick With Delayed $2.6bn US Pegfilgrastim Entry
With its pure partnered approach, US-based player Amneal has tallied up its third biosimilar launch in the market.
Amneal Eyes Multiple Targets As It Seeks To Maintain Momentum
As Amneal reported first-quarter results, the firm’s management pointed to a number of specific product opportunities on the horizon as the company seeks to maintain growth momentum.
Celltrion CCO On The Big US Build-Up, Direct Sales Model
Celltrion USA’s chief commercial officer Thomas Nusbickel tells Scrip how he’s shaping the South Korean group’s operations ahead of key launches that include assets in the immunology segment. He also weighs in on whether big pharma will stay in the biosimilars game over the long term.
Proud Amneal Offers Preview Of Q1 Growth
Ahead of revealing its full first-quarter results, Amneal has released limited preliminary details of its financials for the first three months of 2023, pointing to double-digit sales and profit growth in Q1.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Amedra Pharmaceuticals LLC
- Amneal Pharmaceuticals, LLC
- CorePharma LLC
- Gemini Laboratories, LLC
- Impax Generics
- Impax Laboratories, Inc. (IPXL)
- Impax Specialty Pharma
- Lineage Therapeutics Inc.
- Tower Holdings, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.